膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human TSLP R (Luc) HEK293 Reporter Cell was engineered to not only express STAT5 signaling response element, but also express the receptors full length human TSLP R (Gene ID: 64109) and IL-7 R alpha (Gene ID: 3575). When stimulated with human TSLP protein, the TSLP/TSLP R interaction drives STAT5-mediated luminescence. Inhibition of TSLP binding to TSLP R by either anti-TSLP or anti-TSLP R antibodies results in a decrease in luminescence.
应用说明（Application）
Screen for anti-human TSLP or anti-human TSLP R neutralizing antibody
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Zeocin (100 μg/mL) + Puromycin (2 μg/mL)
培养基（Culture Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Co-expression analysis of human TSLP R and IL-7 R alpha on Human TSLP R (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human TSLP R (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-TSLP R antibody and FITC-labeled anti-IL-7 R alpha antibody.
Protocol
Application
Inhibition of human TSLP protein-induced reporter activity by anti-human TSLP neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human TSLP protein (Cat. No. TSP-H52Hb) with a final concentration of 0.3 μg/mL. The EC50 of anti-human TSLP neutralizing antibody is approximately 0.55 μg/mL.
Protocol
Signaling Bioassay
Response to human TSLP protein (RLU).
The Human TSLP R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (Cat. No. TSP-H52Hb). The EC50 was approximately 0.1392 μg/mL.
Protocol
Response to human TSLP protein (Fold).
The Human TSLP R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (Cat. No. TSP-H52Hb). The max induction fold was approximately 45.15
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human TSLP R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein. Human TSLP protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-26.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Thymic stromal lymphopoietin (TSLP) is a pleiotropic cytokine and takes multi-functions via binding to a high-affinity heteromeric complex composed of thymic stromal lymphopoietin receptor (TSLPR) chain and IL-7Rα. The receptor complex on cells co-expressing TSLPR and IL-7Rα activated downstream genes expression and initiate proinflammatory signaling. TSLP involved in a variety of allergic diseases (e.g., atopic dermatitis, bronchial asthma). Further investigation indicated that TSLP is also involved in chronic inflammatory (i.e., chronic obstructive pulmonary disease and celiac disease) and autoimmune (e.g., psoriasis, rheumatoid arthritis) disorders and several cancers.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
